Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico.

After emergency authorization, different COVID-19 vaccines were administered across Mexico in 2021, including mRNA, viral vector, and inactivated platform vaccines. In the state of Baja-California, 3,516,394 doses were administered, and 2285 adverse events (AE) were registered in the epidemiological surveillance system in 2021. Incidence rates per 100,000 doses were calculated for total, mild (local and systemic), and severe AE for each vaccine. Symptoms were compared between mRNA and viral vector/inactivated virus vaccines. The overall incidence rate for all AE was 64.98 per 100,000 administered doses; 79.05 AE per 100,000 doses for mRNA vaccines; and 56.9 AE per 100,000 doses for viral vector/inactivated virus vaccine platforms. AE were at least five times higher in recipients of the AstraZeneca vaccine from the Serum Institute of India (AZ from SII). Local injection site symptoms were more common in mRNA vaccines while systemic were more prevalent in viral vector/inactivated virus vaccines. Severe AE rates were similar across all administered vaccines (0.72-1.61 AE per 100,000 doses), except for AZ from SII, which documented 12.6 AE per 100,000 doses. Among 32 hospitalized severe cases, 28 (87.5%) were discharged. Guillain-Barré Syndrome was the most common serious AE reported (n = 7). Adverse events rates differed among vaccine manufacturers but were consistent with clinical trials and population-based reports in the literature.

Anemia crónica severa / Severe chronic anemia

La anemia crónica severa grado IV, es un problema frecuente en I>N>P. Existe controversia acerca de su manejo, por lo que se revisó la experiencia del servicio de Urgencias del I.N.P., en un periodo de 5 años, 1981 a 1986. Se incluyeron todos los pacientes con hemoglobina igual o menor a 5g% y sintomatología de congestión circulatoria. en un grupo de pacientes se realizó exasanguinotransfusión modificada y en otro transfusión simple. Se midió hemoglobina inicial, final, frecuencia cardiaca y respiratoria y se compararon los resultados de ambos grupos. De un total de 55 pacientes 30 masculinos y 25 femeninos, el padecimiento más frecuente fue la leucemia. No hubo diferencia en los resultados después del tratamiento en los 2 grupos. Se propone un esquema de manejo, medidas generales y corrección de la anemia